Rigel Pharmaceuticals (RIGL) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to loss of $0.40 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 83.78%. A quarter ago, it was expected that this drug developer would post a loss of $0.30 per share when it actually produced a loss of $0.50, delivering a surprise of -66.67%. Over the last four quarters, the comp ...

Exhibit 99.1 Rigel Reports Second Quarter 2024 Financial Results and Provides Business Update · Second quarter total revenue of $36.8 million, which includes TAVALISSE net product sales of $26.4 million, REZLIDHIA net product sales of $5.2 million and GAVRETOnet product sales of $1.9 million · Successfully completed NDA transfer of GAVRETO for the treatment of RET fusion-positive metastatic non-small cell lung cancer and advanced or metastatic thyroid cancer, with product available from Rigel beginning June ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 0-29889 Rigel Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 94-3248524 (Sta ...

Participants can access the live conference call by dialing 877-407-3088 (domestic) or 201-389-0927 (international). The conference call and accompanying slides will also be webcast live and can be accessed from the Investor Relations section of the company's website at www.rigel.com. The webcast will be archived and available for replay for 90 days after the call via the Rigel website. Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing n ...

Core Insights - Rigel Pharmaceuticals, Inc. (RIGL) is a microcap biotech company focused on innovative therapeutics for hematological conditions and cancers, with three main FDA-approved products: Tavalisse, Rezlidhia, and Gavreto [23][24][36] - The company is projected to generate approximately $191.5 million in revenues by 2025, representing a 28.0% year-over-year increase in 2024 revenues, driven by the sales of its products [6][34] - RIGL's current market cap is $177.5 million, with a significant undervaluation compared to its sector's median forward price-to-sales (P/S) multiple of 3.9, as RIGL trades at a 0.9 forward P/S [6][34] Financial Performance - In Q1 2024, RIGL reported net product sales of $26.0 million, with Tavalisse contributing $21.1 million and Rezlidhia $4.9 million [3][31] - The company has a cash position of $49.6 million against $59.7 million in financial debt, resulting in a negative book value of $31.7 million [6][34] - RIGL's quarterly cash burn is estimated at $4.9 million, indicating a cash runway of approximately 2.5 years, which is considered healthy for projected revenue growth [34] Product Pipeline and Development - RIGL's product pipeline includes promising candidates such as R289 for lower-risk myelodysplastic syndromes, targeting IRAK1/4, and milademetan, which completed Phase 1 trials for cancer [15][30][45] - Gavreto, recently acquired by RIGL, is indicated for RET fusion-positive non-small cell lung cancer (NSCLC) and advanced thyroid cancer, with FDA approval requiring confirmatory trial results [2][30] - Rezlidhia has shown efficacy in treating relapsed or refractory acute myeloid leukemia (AML) with a median duration of response of 25.9 months [26][39] Market Outlook - The acute myeloid leukemia market is projected to reach $3.0 billion by 2029, providing a significant opportunity for RIGL to carve out a niche with its products [27][39] - The overall market for RIGL's therapeutic areas is expected to grow at a compound annual growth rate (CAGR) of 10.15%, reaching $2.97 billion by 2029 [27] - RIGL's partnerships with companies like BerGenBio, Eli Lilly, and Daiichi Sankyo enhance its research capabilities and product offerings [17][41]

SOUTH SAN FRANCISCO, Calif., July 12, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to Rigel's Inducement Plan, approved by the Compensation Committee of Rigel's Board of Directors and granted as an inducement material to employees' entering into employment with Rigel, in accordance with NASDAQ Listing Rule 5635(c)(4). Specifically, Rigel granted 79,890 stock options to eleven non-executive employees vesting over four years with ...

Core Viewpoint - Rigel Pharmaceuticals, Inc. will implement a 1-for-10 reverse stock split to increase the per-share trading price of its common stock, effective June 27, 2024, aiming to enhance marketability and compliance with Nasdaq listing requirements [3][8]. Group 1: Reverse Stock Split Details - The reverse stock split was approved by stockholders on May 24, 2024, and the final ratio was confirmed by the Board on June 15, 2024 [1]. - The number of shares outstanding will decrease from approximately 175,582,945 to about 17,558,294 [1]. - The reverse stock split will not change the number of authorized shares or the par value of the common stock [1]. Group 2: Market Impact and Compliance - The primary objective of the reverse stock split is to raise the per-share trading price, which is currently low and affects the company's appeal to institutional investors [8]. - The split is also intended to help maintain compliance with Nasdaq's minimum bid requirement of $1.00 per share [8]. Group 3: Shareholder Actions - Registered stockholders with shares in book-entry form will not need to take action to receive post-split shares [4]. - Stockholders holding shares in "street name" will have their positions automatically adjusted, while those with certificate shares will receive instructions from Equiniti Trust Company [4].

GAVRETO will be available from Rigel in the U.S. beginning June 27, 2024 SOUTH SAN FRANCISCO, Calif., June 24, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced the completion of the transfer to Rigel of the New Drug Application (NDA) for GAVRETO® (pralsetinib) for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) as detected by a U.S. Food and Drug Administration (FDA) approved test ...

- Oral presentation highlighting final five-year efficacy data from the registrational Phase 2 trial of REZLIDHIA® (olutasidenib) in heavily pretreated patients with R/R mIDH1 AML, including those receiving prior venetoclax - New data shows clinically meaningful effect of olutasidenib in patients with mIDH1 AML secondary to MPN and as bridge-to-transplant treatment in patients with R/R mIDH1 AML SOUTH SAN FRANCISCO, Calif., June 14, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today annou ...

Title: Olutasidenib for Mutated IDH1 Acute Myeloid Leukemia: Final Five-Year Results from the Phase 2 Pivotal Cohort Presenter: Jorge E. Cortes, M.D. - Long-term efficacy data from the registrational Phase 2 trial of REZLIDHIA® (olutasidenib) in heavily pretreated patients with R/R mIDH1 AML, including those receiving prior venetoclax - Data from a subgroup analyses of elderly R/R mIDH1 AML patients treated with olutasidenib shows consistent CR/CRh results - Overview of the Phase 1b trial of R289 in patient ...